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Introduction
Recent advances in gene targeting technologies in the
mouse have taken us one leap closer to understanding the
genetic pathways that operate during normal mammary
gland development and tumorigenesis. The possibility to
delete or mutate genes specifically in mammary epithelial
cells and at predetermined time points permits investiga-
tors to analyze the fates of defined cell types in the
absence of confounding systemic effects. Gene deletion
(knockout) and transgenic mice, both alone and in combi-
nation, can be used to address specific questions in
developmental and cancer biology. The genetic ablation of
steroid (estrogen and progesterone) and peptide (pro-
lactin, epidermal growth factor) hormone receptors and
their ligands has provided a deep insight into their function
during ductal and alveolar development and has shed light
on their redundancy and parallel pathways. Finally, the
deletion of transcription factors, including those that
mediate peptide hormone signaling, has revealed distinct
roles in epithelial cell proliferation, differentiation, and
death (for a detailed assessment of genetic approaches to
study mammary development, see [1]). Rather than
describing individual models (an array of mouse models
will be presented in depth in the January 2000 issue of the
journal Oncogene), herein I discuss some of the lessons
we have learned during the past 15 years from the mice
models that are at hand, and the technological hurdles we
now encounter. Like in many explorations, the initial con-
cepts, approaches, and tools are rather crude and need to
be further developed and refined as new information
streams in and new hypotheses are articulated. On the
basis of this need I present contemporary approaches that
should aid our quest to identify and understand molecular
pathways of pathogenesis.
Experiments conducted by Philip Leder and coworkers 15
years ago represent a milestone in breast cancer research
[2]. They fused the long terminal repeat (LTR) of the
mouse mammary tumor virus (MMTV) to the human c-myc
proto-oncogene and incorporated this hybrid gene into
mice. These transgenic mice expressed the human myc
protein in their mammary glands, which resulted in the
development of breast tumors [2]. This landmark paper
helped to establish an entirely new research arena poised
to identify genetic pathways that control breast cancer.
After decades of research on tissue culture cells, both
federal and private funding agencies saw the opportunity
to extend investigations into settings that more closely
resembled the human condition. Fifteen years after the
study by Leder and coworkers, research by Deng (a
former student of Leder) and coworkers set another mile-
stone towards this goal. These investigators succeeded in
inactivating the breast cancer gene Brca1 specifically in
mammary epithelial cells of mice, and they demonstrated
that mammary tumors coincided with genome instability
[3]. The distinct lesson learned from these studies was
that the wrongful expression of an oncogene and the inac-
tivation of a tumor suppressor gene in mice can cause
cancer, just like in humans. However, the myc and Brca1
mice differ in two fundamental aspects from the human
situation. In the myc mice oncogene activity occurs as
early as puberty, whereas in humans genetic changes
leading to cancer may occur later in life. The appearance
of tumors in Brca1 conditional mice depends on the loss
of both alleles, whereas in humans only one BRCA1 allele
is altered (for discussion, see [4]).
Understanding genetic pathways was considered to be,
and still remains the prerequisite for the development ofhttp://breast-cancer-research.com/content/2/1/002
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molecular and pharmacological agents to treat and
prevent cancer. Over the past 15 years almost 100 mouse
models have been generated that permit the investigation
of defined aspects of tumorigenesis. The impact of trans-
genic mouse models on breast cancer research was the
topic of recent conferences in Annapolis, Maryland (March
3–5, 1999) and Bar Harbor, Maine, USA (The Jackson
Laboratory Conference on ‘Cancer of the Mammary
Gland’, October 5–8, 1999) [5]. It is fair to say that not a
single model by itself covers the full spectrum of this
disease, but that individual models address distinct
aspects. Each transgene targets different signaling path-
ways outside and inside the mammary cell, and disrupts
these pathways at different time points during develop-
ment. In addition, the concomitant disruption of some
physiologic parameters provided insight into the cellular
requirements for cellular transformation to occur.
At the Annapolis conference, pathologists and basic
researchers convened and assessed different mouse
models. Specifically, they asked the following key ques-
tion: How similar are mouse models to the human condi-
tion? A panel of nine medical and veterinary pathologists
with expertise in mammary gland biology reviewed material
representing more than 90% of the mouse models. A
nomenclature was developed and recommendations for
future analyses were drafted. The consensus report from
the Annapolis meeting, including the ‘Annapolis guide-
lines’ will be published in an upcoming issue of the journal
Oncogene [6]. It is suggested that the Annapolis nomen-
clature is adopted by the research community and in fed-
erally funded research. In addition, the recent
development of a web-based interactive histology atlas [7]
now permits the comparison of high-resolution images
from mouse models and human breast cancer, and
researchers in different locations can view, discuss, anno-
tate, and compare histologic images in real time. The his-
tology atlas in conjunction with the database for
genetically engineered mice [8] will provide in depth infor-
mation on genetic pathways in human breast cancer and
corresponding mouse models.
In comparing the biology from human breast tumors with
that of mammary tumors in genetically engineered mice, the
Annapolis pathologists identified similarities and differences
(Table 6 in [6]). Among the similarities identified are as
follows: molecular lesions that cause breast cancer in
humans can also cause cancer in genetically engineered
mice; lesions in both species display similar morphologic
patterns; multi-hit kinetics of cancer development; mammary
cancers in both species are metastatic; and mammary
cancer is frequently hormone independent. Among the dif-
ferences are as follows: some molecular lesions that cause
mammary cancer in mice have not been found in human
mammary cancer; the morphology of most mouse tumors
does not resemble that of common human cancers; some
transgenes in mouse appear to be associated with single-hit
kinetics; most mouse tumors metastasize to the lung,
whereas most human tumors metastasize to the lymph
nodes; and half of the human cancers are hormone
independent, but most mouse tumors are hormone depen-
dent. Although many transgenic mice display dissimilarities
to the human condition, it is likely that their usefulness
extends into understanding molecular pathways that lead to
cancer initiation and progression. For example, the viral
oncogene that encodes the SV40 T antigen cannot be
linked to human breast cancer, but the respective trans-
genic mice provide insight into cell-cycle control during
hyperplasia and tumor progression (see below).
Models at hand
Many of the models that have been used to date are pre-
sented in Table 1, and will be discussed in detail in a
special edition of the journal Oncogene, which will be
published in January, 2000. It is necessary to consider
several variables in assessing a genetically engineered
model. Most notably, the nature of the transgene deter-
mines the developmental and/or tumorigenic phenotype.
The regulatory region controlling transgene expression
defines the cell type affected and the temporal onset of
the phenotype. Because there is experimental evidence to
suggest that tumor progression is a multistep process
probably involving different signaling pathways,
researchers have generated mice that carry more than one
transgene. Again, the pioneering study came from the lab-
oratory Leder and coworkers in 1987 [9], and demon-
strated the synergism between the oncoproteins myc and
ras. Gain of function studies in transgenic mice that carry
growth regulators or oncogenes address only one aspect
of tumorigenesis, and the role of tumor suppressor genes
and the presence of endogenous hormonal signaling
cannot be ignored. Experimentally these issues are
addressed through the deletion of tumor suppressor
genes and the genetic ablation of endogenous hormone
signaling pathways.
Several lessons can be learned from the mice presented in
Table 1. First, oncoproteins, and growth and cell-cycle regu-
lators in general can induce mammary tumors in transgenic
mice. This points to a general susceptibility of mammary
tissue to transformation and may be explained by the plas-
ticity and cyclic development of this organ. With each preg-
nancy a functional organ rises from a population of stem
cells, only waiting to be fully dismantled after weaning. Both
processes require coordinated activity of the genetic path-
ways that control cell proliferation, differentiation and death,
and mechanisms of protease-mediated remodeling. It is
therefore no surprise that transgene-mediated disruption of
any of these processes can trigger transformation of the
gland. This point is reinforced by several transgenic mice
that carry metallothionein (MT)-driven transgenes. Although
the MT promoter is active in most cell types, the appear-Breast Cancer Research    Vol 2 No 1 Hennighausen
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ance of mammary hyperplasia and tumors is among the pre-
dominant phenotypes in these mice.
The second lesson focuses on the positional and temporal
effect of an oncogenic stimulus. Depending on the pro-
moter, the transgene is activated in ductal and alveolar cells
[MMTV-LTR, C(3)1], preferentially in alveolar cells [whey
acidic protein (WAP), beta lactoglobulin (BLG)], or in a
large variety of cells (MT). In addition, high activity of MMTV-
driven transgenes can be detected earlier than WAP-
controlled genes. The consequences of such differences
are exemplified by the int3/notch4 gene, in that MMTV-int3
Table 1
Description of genetically engineered mice that develop mammary hyperplasias and tumors
1st 2nd 1st gene 2nd gene 
Active protein transgene transgene knockout knockout Promoters
Growth factors TGF-a p53, myc Stat5a MT, WAP,
MMTV-LTR
TGF-b WAP, MMTV
FGF-3 (INT2) wnt1 MMTV-LTR
FGF-7 (KGF) MMTV-LTR
FGF-8 MMTV-LTR
Heregulin (NDF) myc MMTV-LTR
HGF MT
IGF-I WAP
IGF-II BLG
c-src MMTV-LTR
PyV-mT Prl MMTV-LTR
Receptors TGF-b DNIIR MMTV-LTR
ERB-B2 (neu) p53 MMTV-LTR, WAP
RET MMTV-LTR
Tpr-MET MT
Viral oncogenes SV40 Tag bcl-2 p53, bax WAP, C(3)1
PyV-mT c-src, c-yes MMTV-LTR
PyV-T MMTV-LTR
SV40 Tag (tetop) TTA MMTV-LTR
Cell cycle Cyclin D1 MMTV-LTR
Cyclin A Cdk2 BLG
Cyclin E BLG
mdm2 E2F1 BLG
Myc ras MMTV
p53 172H Bcl-2 WAP
Differentiation Notch 4 (Int3) TGF-b pRb WAP, MMTV
Wnt1 FGF-3 p53, pRb, ER MMTV-LTR
Wnt 10b MMTV-LTR
Others Stromelysin WAP
Ras myc WAP, MMTV
Tumor suppressor Cre Brca1 p53 WAP, MMTV
Cre Brca1 pRb WAP, MMTV
The biology of many of these models are described in a special issue of Oncogene to be published in January, 2000, and the comparative
histology is discussed in [5]. BLG, beta lactoglobin; FGF, fibroblast growth factor; IGF, insulin-like growth factor; KGF, k growth factor; LTR, long
terminal repeat; MMTV, mouse mammary tumor virus; MT, metallothionein; NDF, neu differentiation factor; WAP, whey acidic protein; TGF,
transforming growth factor.mice have an early onset of tumorigenesis and do not form
alveolar structures, whereas WAP-int3 mice develop tumors
later and exhibit lobuloalveolar compartments.
The third lesson centers on the identification of parallel
and interconnected pathways through the generation of
bitransgenic and gene deletion mice. Synergism of two
different oncoproteins revealed two-hit kinetics and paral-
lel pathways (eg ras and myc, and transforming growth
factor-a and myc), and the deletion of Stat5a in the back-
ground of transforming growth factor-a transgenic mice
linked the epidermal growth factor receptor and the
Jak2/Stat5 pathway in tumor progression.
Lessons from mouse mammary tumor virus
and its ‘tagged’ genes
The first mouse strains that had a high incidence of
mammary tumors were not transgenic mice, but rather
were certain inbred strains developed more than 60 years
ago at the Jackson Laboratory in Bar Harbor, Maine. Bit-
tner’s original demonstration of the ‘milk factor’ in mouse
strains that had a high incidence of mammary tumors led
to the discovery of the MMTV [10]. Proviruses of MMTV
are integrated in the mouse genome and, as somatic
‘genetic mutagens’, they have the capacity to activate jux-
taposed cellular genes, which can function in some cases
as oncogenes. Originally MMTV was used as a ‘molecular
tag’ to identify those genes that had been disrupted as a
consequence of proviral insertion [11]. Several classes of
molecules were identified and they include Wnt proteins,
members of the Fgf family, and cell fate proteins of the
Notch type (reviewed in [12]). The first protein to be iden-
tified in MMTV-induced tumors was Wnt1, a protein that
signals through a receptor called Frizzled (Fz) and the b-
catenin pathway. The Wnt1 signaling molecule has played
an exceptional role in our understanding of the synergy
between signaling pathways. MMTV-wnt1 transgenic
mice, which develop hyperplasia and tumors early in life,
have been bred with many other transgenic and gene
knockout mice, and a wealth of information on signaling
pathways has emerged. For example, as with other trans-
genes, wnt1 synergizes with Fgf signals, but it does not
depend on the presence of the estrogen receptor (ER)-a,
suggesting that tumor progression is independent of
estrogen. More recently, however, a second form of the
ER was discovered and its role remains obscure. In addi-
tion, p53-mediated cell death has been demonstrated in
wnt1-induced tumors (see The cell cycle, below).
The lesson learned from studies with the MMTV (viral
infections and transgenic experiments) centers on cooper-
ating pathways that are operative during tumor progres-
sion [12]. In particular, the infection of wnt1 transgenic
mice with MMTV has led to the identification that
members of the Fgf family are the preferred cooperative
partners in the dysregulation of normal growth control. The
infection of new and improved mouse models, such as the
conditional Brca1 mice, with MMTV may result in the iden-
tification of additional growth regulators that are relevant
to human breast cancer. Although this approach has not
recently yielded new genes in the context of the wnt1
transgenic mice, the outcome with other transgenic and
knockout mice cannot be predicted. Because the fre-
quency with which the common integration sites for
MMTV are rearranged by the virus in mammary tumors is
dependent on the host strain [12], it could also be possi-
ble to use this system to identify genetic modifiers.
The cell cycle
Disrupting the cell cycle is an obvious strategy for a tumor
cell to escape growth control. A variety of oncogenes do
precisely this, and have therefore been choice genes for
expression in transgenic mice. Some of them have obvious
links to human cancers, such as those that encode myc
and cyclins; the use of others, though, such as the viral
oncogenes, is less direct. It was vital to use viral onco-
genes in the early days of transgenesis, however, because
they disrupt key nuclear and cytoplasmic signaling path-
ways that are operative in human cancer. These studies
provide critical insight into global growth control networks.
Mice that express the SV40 T antigen led to an under-
standing of cell-cycle regulation during tumor progression
and provided compelling evidence that both p53-depen-
dent and p53-independent pathways are operative in
mammary tissue.
The tumor suppressor gene p53 is mutated in approxi-
mately 50% of primary human breast cancers. Its role in
mouse models has been addressed through the expres-
sion of viral oncogenes that bind to and thus inactivate
p53. However, SV40 T antigen dismantles the cell cycle
through binding to, and thus the inactivation of several key
regulators, including p53 and pRb, which makes it difficult
to dissect the contribution of individual components. In
order to address the role of p53 specifically, researchers
deleted one or two copies of the gene in the presence of
different transgenes, including myc, ras, and wnt. In
general, the absence of one or two p53 alleles did not
accelerate the formation of mammary tumors, but it did
accelerate tumorigenesis in other organs, such as the sali-
vary gland. The only acceleration of mammary tumors in
transgenic mice in the absence of functional p53 was
observed in context of the wnt1 transgene, suggesting
that p53-dependent cell death is critical in this genetic
framework. Although the presence of p53 is not critical for
cell death in mammary tissue that proceeds during involu-
tion, it may well contribute to cell death after the introduc-
tion of genomic lesions. Deletion of both alleles of the
Brca1 gene from mammary tissue leads to tumors after
approximately 1 year [3]. The concomitant deletion of one
copy of p53 accelerates tumor formation, which is often
accompanied by the loss of the second allele.
http://breast-cancer-research.com/content/2/1/002
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Hormonal signaling and cancer
It is well established that the presence of estrogen is a risk
factor for mammary tumorigenesis. However, its exact mol-
ecular action and the entirety of signaling pathways that
are affected is not understood. The availability of the ER-a
and ER-b knockout mice, in conjunction with transgenic
oncomice should provide some of the answers. Studies
with ER-a-null mice and the wnt1 oncogene have demon-
strated that the presence of a strong oncogenic stimulus
does not require the synergism of the ER-a. Experiments
with less potent oncoproteins and natural lesions, such as
the deletion of the Brca1 gene, will provide further insight
into the modulatory role of estrogens. Prolactin signals
through the Jak2/Stat5 pathway is required for functional
development of mammary tissue. A role of prolactin in
tumor initiation and/or progression had been proposed,
and recent experiments using transgenic mice and both
prolactin-null and Stat5a-null mice have confirmed this.
The course ahead
The tidal wave of transgenic studies has provided a wealth
of information about molecular pathways and cancer physi-
ology. These studies have also revealed problems inherent
in transgenic mice and technical challenges that have to be
met. The challenges come in different categories, which
include the variable biology of mouse strains, the different
expression pattern of transgenes, and the development of
new technologies to control multiple genes simultaneously.
There is no longer any doubt that the nature of the mouse
strain can greatly influence the latency and even the type of
the tumor caused by the transgenic oncoprotein. This was
not an apparent problem in the early days of transgenesis
(mice were generated in only a few inbred backgrounds
and in C57BL/6 × SJL hybrids), when investigators
studied mice that carried individual transgenes. More
recently, however, investigators have studied mice that
carry several transgenes and gene deletion mutations that
are normally generated through complex breeding strate-
gies. This resulted in the introduction of the 129 strain
background, which clearly behaves in a different manner
from that of the classic FVB/N transgenic strain. Concerted
effort is being made by investigators and centers, such as
the Jackson Laboratory, to breed all transgenic and gene
knockout strains into the 129 and C57BL/6 background,
accelerated through the use of speed congenics. The dis-
covery of distinct strain differences also provides an oppor-
tunity to identify modifier genes in a defined setting that is
not possible in humans. The power of such systems has
been demonstrated with the adenomatous polyposis coli
(APC)/multiple intestinal neoplasia (min) locus. By crossing
the Apcmin/+ locus from the C57BL/6J strain into other
inbred strains, strong variations in adenoma multiplicity
were observed.
Biologic challenges include the dissection of the role of
individual cell types in mammary tissue in the process of
tumor progression. Gene knockout and transplant studies
have revealed a cross-talk between the stroma and the
epithelium (both compartments themselves consist of
several cell types). At this point, however, the choice of
promoters to target transgenes is restricted to those that
are specific to epithelial cells. In addition to the LTR of the
MMTV, promoters from milk protein genes (WAP, b-lac-
toglobulin,  b-casein) and the C3(1) promoter have been
used to control transgenes. Expression of these control
elements is targeted to the mammary epithelium and
enhanced by lactogenic hormones. As a result, in many
cases the tumor latency is slightly shorter in multiparous
mice. In addition, the temporal – and perhaps spatial –
activity of these promoters is distinct, which determines the
target of the oncogenic stimulus. It is time to initiate a
search for promoters that target transcription preferentially
to stroma cells (adipocytes and fibroblasts) in the
mammary gland. Since mammary stroma probably has
unique features that distinguish it from adipocytes within
other organs, it will be necessary to identify genes with
expression that is specific to this compartment. It is experi-
mentally possible to clear the epithelium from the mammary
fat pad, and thus identify genes that are expressed within
the stroma at different developmental stages. One ongoing
effort of the Mammary Genome Program is the identifica-
tion of expressed sequence tags that are expressed in
stromal structures [13]. The large-scale expressed
sequence tag programs currently underway in the mouse
may be the best way to identify genes with expression that
is confined (or preferential) to the mammary stroma.
While transgenes allow us to study tumor initiation and
progression, a necessary and overdue focus needs to be
on investigations into how to dismantle a solid tumor in an
in vivo setting. The experiments ahead are obvious, and
involve the cell-specific activation and inactivation of regu-
latory genes, including tumor suppressor genes. Those
experiments would include the reversal of the tumor phe-
notype through the subsequent inactivation of the onco-
gene or restoration of the tumor suppressor activity. The
benefits of such strategies are obvious and would permit
the possible identification of those genes that contribute
to the multistage process that is eventually irreversible.
Progress has been made in the salivary gland through the
temporal activation/inactivation of the viral oncogene that
encodes SV40 T antigen [14]. Dependable time-sensitive
gene switches for mammary cell types have not yet been
developed, however. A step in this direction was taken by
Lee and coworkers [15]. This group generated mice that
carry the reverse tetracycline time switch under control of
the WAP gene promoter. The same mice also carried the
Cre recombinase gene under the tet switch. The availabil-
ity of tools that permit the manipulation of genes specifi-
cally in mammary cells in the mouse [16] and at defined
time points [15] will have a sound impact in the biology of
the mammary gland. These tools will permit researchersfor the first time to delete (and reactivate) genes in the
cell-specific and time-specific manner. Traditional knock-
out experiments based on embryonic stem cell-based
gene targeting permitted the identification of ‘early’ gene
functions, but not those that were suspected subsequent
to the observed defect. For example, in the absence of
functional Stat5a, mammary development is abrogated
and mice do not lactate [17]. These studies did not
provide any information regarding whether Jak2/Stat5a
signaling is required for the maintenance of lactation,
however. Using temporal tools it should now be possible
to maintain Stat5 function throughout pregnancy and
delete it after established lactation.
One major hurdle centers on the simultaneous inactivation
of several members of a given gene family, such as cell
survival factors from the bcl-2 family. Because these
genes are found at different locations, a knockout
approach is inherently difficult. To modulate expression
from several genes simultaneously it may be necessary to
revisit the antisense strategy, and to develop appropriate
transgenic vectors.
After 15 years of innovative, intensive and productive
research the mammary community has identified genetic
pathways of breast cancer, and therapeutic and preventive
compounds are now being tested in mouse models [18].
Our understanding of the pathways that control normal
mammary physiology in the mouse and human is still rudi-
mentary, and we are only at the beginning of the road to
replicating human cancer in mice. Whereas researchers in
the 20th century focused on the identification of signals
and genetic pathways that control mammary development,
researchers in the 21st century will need to focus on the
interphase of normal physiology and cancer.
Acknowledgements
The author thanks the members of his laboratory, and Bob Cardiff and
Priscilla Furth for continuously establishing new challenges and thoughtful
discussions.
References
1. Hennighausen L, Robinson GW: Think globally, act locally: the
making of a mouse mammary gland. Genes Dev 1998, 12:449–455.
2. Stewart TA, Pattengale PK, Leder P: Spontaneous mammary
adenocarcinomas in transgenic mice that carry and express
MTV/myc fusion genes. Cell 1984, 38:627–637.
3. Xu X, Wagner KU, Larson D, et al: Conditional mutations of Brca1 in
mammary epithelial cells results in blunted ductal morphogenesis
and tumor formation. Nature Genet 1999, 22:37–43.
4. Gusterson B, Howard B, Crook T, Tennent B: http://breast-cancer-
research.com/vol1no1/02jul99/dispatch/1, 1999.
5. Annapolis Guidelines (http://mammary.nih.gov/Annapolis-guidelines)
6. Cardiff RD, Anver MR, Gusterson BA, et al: The mammary pathology
of genetically engineered mice: the consensus report and recom-
mendation from the Annapolis meeting. Oncogene 2000 (in press).
7. Interactive Histology Atlas (http://histology.nih.gov).
8. Genetically engineered mice (http://cancermodels.nih.gov).
9. Sinn E, Muller W, Pattengale P, et al: Coexpression of MMTV/v-Ha-
ras and MMTV/c-myc genes in transgenic mice: synergistic action
of oncogenes in vivo. Cell 1987, 49:465–475.
10. Bittner JJ: Science 1936, 34:162.
11. Varmus HE: Cancer Surv 1982, 1:309–320.
12. Callahan R, Smith G: MMTV-induced mammary tumorigenesis:
gene discovery, progression to malignancy and cellular pathways.
Oncogene 2000 (in press).
13. Biology of the Mammary Gland (http://mammary.nih.gov).
14. Ewald D, Li M, Efrat S, et al: Time sensitive reversal of hyperplasia
in transgenic mice expressing SV40 T antigen. Science 1996,
273:1384–1386.
15. Utomo ARH, Nikitin AY, Lee W-H: Temporal, spatial, and cell type-
specific control of Cre-mediated DNA recombination in transgenic
mice. Nature Biotech 1999, 17:1091–1096.
16. Wagner KU, Wall RJ, St. Onge L, et al: Cre mediated deletion in the
mammary gland. Nucleic Acids Res 1997, 25:4323–4330.
17. Liu X, Robinson GW, Wagner KU, et al: Stat5a is mandatory for
adult mammary gland development and lactogenesis. Genes Dev
1997, 11:179–186.
18. Bearss DJ, Subler MA, Hundley JE, Troyer DA, Salinas RA, Windle JJ:
Genetic determinants of response to chemotherapy in transgenic
mouse mammary and salivary tumors. Oncogene 2000 (in press).
Author’s affiliation: Laboratory of Genetics and Physiology, National
Institute of Diabetes, Digestive and Kidney Diseases, National
Institutes of Health, Bethesda, Maryland, USA
Correspondence: Lothar Hennighausen, Laboratory of Genetics and
Physiology, Building 8, Room 101, National Institute of Diabetes,
Digestive and Kidney Diseases, National Institutes of Health, Bethesda,
MD 20892, USA. Tel: +1 301 496 2716; fax: +1 301 480 7312;
e-mail: hennighausen@nih.gov
http://breast-cancer-research.com/content/2/1/002
7